{"transactions":[{"id":737885,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:30:04.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":19188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":19188,"derivative":{"exercise_price":24.11,"expiration_date":"2036-06-10","underlying":"Common Shares","underlying_shares":19188},"source":{"system":"sec-edgar","filing":"0001193125-26-271154","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271154/ownership.xml","form_type":"4"}},{"id":737884,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-06-15T20:30:04.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":4666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date."}],"balance_after":24289,"source":{"system":"sec-edgar","filing":"0001193125-26-271154","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000119312526271154/ownership.xml","form_type":"4"}},{"id":767804,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-05-21T21:00:08.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":12000,"derivative":{"exercise_price":42.26,"exercise_date":"2027-05-19","expiration_date":"2036-05-19","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001517790-26-000002","document":"form4-05212026_050504.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000151779026000002/form4-05212026_050504.xml","form_type":"4"}},{"id":767803,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-21T21:00:08.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":32750,"source":{"system":"sec-edgar","filing":"0001517790-26-000002","document":"form4-05212026_050504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000151779026000002/form4-05212026_050504.xml","form_type":"4"}},{"id":1074154,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:39:57.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6235,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.03,"underlying":"Common Stock","underlying_shares":6235},"source":{"system":"sec-edgar","filing":"0000950170-25-102485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017025102485/ownership.xml","form_type":"4"}},{"id":1074153,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:39:57.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24310,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.03,"underlying":"Common Stock","underlying_shares":24310},"source":{"system":"sec-edgar","filing":"0000950170-25-102485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017025102485/ownership.xml","form_type":"4"}},{"id":1074152,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:39:57.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13928,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.03,"underlying":"Common Stock","underlying_shares":13928},"source":{"system":"sec-edgar","filing":"0000950170-25-102485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017025102485/ownership.xml","form_type":"4"}},{"id":1074151,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:39:57.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":2.19,"underlying":"Common Stock","underlying_shares":33875},"source":{"system":"sec-edgar","filing":"0000950170-25-102485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017025102485/ownership.xml","form_type":"4"}},{"id":1074150,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:39:57.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18068,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.38,"underlying":"Common Stock","underlying_shares":18068},"source":{"system":"sec-edgar","filing":"0000950170-25-102485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017025102485/ownership.xml","form_type":"4"}},{"id":1074149,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:39:57.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24073,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.39,"underlying":"Common Stock","underlying_shares":24073},"source":{"system":"sec-edgar","filing":"0000950170-25-102485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017025102485/ownership.xml","form_type":"4"}},{"id":1074148,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-05T13:39:57.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents Restricted Stock Units (\"RSUs\"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents Restricted Stock Units (\"RSUs\"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-102485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017025102485/ownership.xml","form_type":"4"}},{"id":1109862,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:30:07.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":75187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":75187,"derivative":{"exercise_price":7.3,"expiration_date":"2035-06-11","underlying":"Common Shares","underlying_shares":75187},"source":{"system":"sec-edgar","filing":"0000950170-25-086765","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025086765/ownership.xml","form_type":"4"}},{"id":1117502,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-06-10T00:44:53.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":30000,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001746473-25-000132","document":"wk-form4_1749516282.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000174647325000132/wk-form4_1749516282.xml","form_type":"4"}},{"id":1134843,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-24T00:44:02.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock.  The shares shall vest upon the earlier to occur of (i) May 22, 2026 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000950170-25-077274","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017025077274/ownership.xml","form_type":"4"}},{"id":1145190,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-05-16T23:00:08.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":19500,"derivative":{"exercise_price":21.15,"exercise_date":"2026-05-15","expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001415889-25-013497","document":"form4-05162025_070505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925013497/form4-05162025_070505.xml","form_type":"4"}},{"id":1145189,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-16T23:00:08.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":28750,"source":{"system":"sec-edgar","filing":"0001415889-25-013497","document":"form4-05162025_070505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588925013497/form4-05162025_070505.xml","form_type":"4"}},{"id":1226877,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-03-04T22:09:31.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":33875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option award was issued pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation, and the shares subject to this award vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter occurring hereafter, with the first installment vesting on March 31, 2025."}],"balance_after":33875,"derivative":{"exercise_price":2.19,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":33875},"source":{"system":"sec-edgar","filing":"0000950170-25-032417","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017025032417/ownership.xml","form_type":"4"}},{"id":1476945,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2024-06-18T00:15:21.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":26764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":26764,"derivative":{"exercise_price":13.06,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":26764},"source":{"system":"sec-edgar","filing":"0001746473-24-000101","document":"wk-form4_1718669714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000174647324000101/wk-form4_1718669714.xml","form_type":"4"}},{"id":1482185,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T20:10:00.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":16506,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Company's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Company's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":16506,"derivative":{"exercise_price":7.25,"expiration_date":"2034-06-09","underlying":"Common Shares","underlying_shares":16506},"source":{"system":"sec-edgar","filing":"0000950170-24-072441","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000095017024072441/ownership.xml","form_type":"4"}},{"id":1486243,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-06-07T21:05:09.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":18068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's 2021 Stock Option and Incentive Plan. The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 5, 2025 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":18068,"derivative":{"exercise_price":3.38,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":18068},"source":{"system":"sec-edgar","filing":"0000950170-24-070841","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017024070841/ownership.xml","form_type":"4"}},{"id":1520552,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-05-10T20:05:26.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under Issuer's Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":19500,"derivative":{"exercise_price":6.82,"exercise_date":"2025-05-08","expiration_date":"2034-05-07","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001415889-24-012845","document":"form4-05102024_040513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924012845/form4-05102024_040513.xml","form_type":"4"}},{"id":1520551,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-10T20:05:26.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under Issuer's Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":22250,"source":{"system":"sec-edgar","filing":"0001415889-24-012845","document":"form4-05102024_040513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000141588924012845/form4-05102024_040513.xml","form_type":"4"}},{"id":1524443,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:35.000Z","date":"2024-05-03","kind":"grant","planned":false,"acquired":true,"shares":13928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date.  Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":13928,"derivative":{"exercise_price":3.03,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":13928},"source":{"system":"sec-edgar","filing":"0000950170-24-054699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017024054699/ownership.xml","form_type":"4"}},{"id":1524442,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:35.000Z","date":"2024-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":0,"derivative":{"exercise_price":10,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":13928},"source":{"system":"sec-edgar","filing":"0000950170-24-054699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017024054699/ownership.xml","form_type":"4"}},{"id":1524441,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:35.000Z","date":"2024-05-03","kind":"grant","planned":false,"acquired":true,"shares":6235,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date.  Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award was issued pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this stock option award are fully vested and exercisable as of the date hereof."}],"balance_after":6235,"derivative":{"exercise_price":3.03,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":6235},"source":{"system":"sec-edgar","filing":"0000950170-24-054699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017024054699/ownership.xml","form_type":"4"}},{"id":1524440,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:35.000Z","date":"2024-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6235,"price":7.618,"value":47498.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award was issued pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this stock option award are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":11.87,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":6235},"source":{"system":"sec-edgar","filing":"0000950170-24-054699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017024054699/ownership.xml","form_type":"4"}},{"id":1524439,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:35.000Z","date":"2024-05-03","kind":"grant","planned":false,"acquired":true,"shares":24310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date.  Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable in thirty-six (36) equal monthly installments, with the first installment having vested on August 27, 2022."}],"balance_after":24310,"derivative":{"exercise_price":3.03,"expiration_date":"2032-07-27","underlying":"Common Stock","underlying_shares":24310},"source":{"system":"sec-edgar","filing":"0000950170-24-054699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017024054699/ownership.xml","form_type":"4"}},{"id":1524438,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:35.000Z","date":"2024-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable in thirty-six (36) equal monthly installments, with the first installment having vested on August 27, 2022."}],"balance_after":0,"derivative":{"exercise_price":6.93,"expiration_date":"2032-07-27","underlying":"Common Stock","underlying_shares":24310},"source":{"system":"sec-edgar","filing":"0000950170-24-054699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017024054699/ownership.xml","form_type":"4"}},{"id":1594505,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant (Right to Buy)","published_at":"2024-03-05T23:01:13.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":24073,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2024."}],"balance_after":24073,"derivative":{"exercise_price":3.39,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":24073},"source":{"system":"sec-edgar","filing":"0000950170-24-026438","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000095017024026438/ownership.xml","form_type":"4"}},{"id":1845347,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T21:39:25.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":19203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option shall vest in twelve (12) equal monthly installments starting from the grant date or upon the next Annual Meeting date, if earlier, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the\" Reverse Stock Split\"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":27267,"derivative":{"exercise_price":3.61,"expiration_date":"2033-06-20","underlying":"Common Shares","underlying_shares":19203},"source":{"system":"sec-edgar","filing":"0000899243-23-016417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924323016417/doc4.xml","form_type":"4"}},{"id":1845346,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2023-06-23T21:39:25.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":13671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one Common Share of the Issuer. The RSUs shall vest in four (4) equal quarterly installments from the grant date or upon the next Annual Meeting date, if earlier, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On August 26, 2022, the Issuer effected a 1-for-15 reverse stock split (the\" Reverse Stock Split\"). The number of securities reported on the Form 4 have been adjusted to reflect the Reverse Stock Split."}],"balance_after":19623,"source":{"system":"sec-edgar","filing":"0000899243-23-016417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924323016417/doc4.xml","form_type":"4"}},{"id":1860128,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant (Right to Buy)","published_at":"2023-06-09T20:15:05.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":13928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":13928,"derivative":{"exercise_price":10,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":13928},"source":{"system":"sec-edgar","filing":"0000899243-23-015174","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000089924323015174/doc4.xml","form_type":"4"}},{"id":1861859,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-08T21:06:20.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting."}],"balance_after":14000,"derivative":{"exercise_price":23.09,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-23-035501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000120919123035501/doc4.xml","form_type":"4"}},{"id":1884442,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-05-19T20:05:18.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":13500,"derivative":{"exercise_price":17.11,"exercise_date":"2024-05-17","expiration_date":"2033-05-16","underlying":"Common Stock","underlying_shares":13500},"source":{"system":"sec-edgar","filing":"0001209191-23-030949","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123030949/doc4.xml","form_type":"4"}},{"id":1884441,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-19T20:05:18.000Z","date":"2023-05-17","kind":"grant","planned":false,"acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":15750,"source":{"system":"sec-edgar","filing":"0001209191-23-030949","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919123030949/doc4.xml","form_type":"4"}},{"id":1971961,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant (Right to Buy)","published_at":"2023-03-03T22:13:34.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":6235,"price":7.618,"value":47498.23,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2023."}],"balance_after":6235,"derivative":{"exercise_price":11.87,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":6235},"source":{"system":"sec-edgar","filing":"0000899243-23-007029","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000089924323007029/doc4.xml","form_type":"4"}},{"id":2185740,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director's Deferred Share Units","published_at":"2022-08-16T01:55:04.000Z","date":"2022-08-11","kind":"grant","acquired":true,"shares":503773,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Represents Directors' Deferred Share Units (\"DDSUs\") granted pursuant to the Issuer's Directors' Deferred Share Unit Plan (the \"Plan\"), effective April 16, 2021. DDSUs will vest 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter. The DDSUs are to be settled in cash upon the termination of the Reporting Persons' directorship (each DDSU representing the right to receive the cash equivalent of the fair market value of one Common Share). Pursuant to the Plan, the fair market value of a Common Share is equal to the volume weighted average trading price of a Common Share on the NEO exchange for the five business days immediately preceding the DDSUs vesting date. The DDSUs granted expire no later than 90 days after the Reporting Person's termination date or such other reasonable time as may be determined by the Administrators (defined in the Plan)."}],"balance_after":503773,"derivative":{"underlying":"Common Shares"},"source":{"system":"sec-edgar","filing":"0000899243-22-028727","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322028727/doc4.xml","form_type":"4"}},{"id":2185739,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-16T01:55:04.000Z","date":"2022-08-11","kind":"grant","acquired":true,"shares":120968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The option grant has an exercise price of $0.84 Canadian Dollars. This represents the exercise price in United States Dollars."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option shall vest and become exercisable 1/3 on August 11, 2023, with the remaining portion vesting in equal monthly installments over the two years thereafter, subject to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":120968,"derivative":{"exercise_price":0.66,"expiration_date":"2032-08-10","underlying":"Common Shares","underlying_shares":120968},"source":{"system":"sec-edgar","filing":"0000899243-22-028727","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322028727/doc4.xml","form_type":"4"}},{"id":2185738,"issuer":{"id":3884,"kind":"organization","name":"Definium Therapeutics, Inc.","symbol":"DFTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-08-16T01:55:04.000Z","date":"2022-08-11","kind":"grant","acquired":true,"shares":89286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one Common Share of the Issuer. These RSUs will vest in three equal annual installments over such three-year period; provided, that in the event that the Reporting Person's continuous service as a member of the Board terminates for any reason other than for cause after the first anniversary of the grant date, a portion of these RSUs that would have vested on the next annual vesting date following the date of departure will immediately vest in full as of the date of termination of service on a prorated basis."}],"balance_after":89286,"source":{"system":"sec-edgar","filing":"0000899243-22-028727","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1813814/000089924322028727/doc4.xml","form_type":"4"}},{"id":2200763,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant (Right to Buy)","published_at":"2022-07-28T12:36:50.000Z","date":"2022-07-27","kind":"grant","acquired":true,"shares":24310,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in thirty-six (36) equal monthly installments, with the first installment vesting on August 27, 2022."}],"balance_after":24310,"derivative":{"exercise_price":6.93,"expiration_date":"2032-07-26","underlying":"Common Stock","underlying_shares":24310},"source":{"system":"sec-edgar","filing":"0000899243-22-026937","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000089924322026937/doc4.xml","form_type":"4"}},{"id":2225012,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T20:15:17.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters beginning October 1st and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 16, 2022 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting."}],"balance_after":15000,"derivative":{"exercise_price":6.8,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-013190","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000156761922013190/doc1.xml","form_type":"4"}},{"id":2273412,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-05-13T00:20:19.000Z","date":"2022-05-11","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":9000,"derivative":{"exercise_price":21.38,"exercise_date":"2023-05-11","expiration_date":"2032-05-10","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-22-028686","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122028686/doc4.xml","form_type":"4"}},{"id":2273411,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-13T00:20:19.000Z","date":"2022-05-11","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":11250,"source":{"system":"sec-edgar","filing":"0001209191-22-028686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919122028686/doc4.xml","form_type":"4"}},{"id":2551342,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-04T20:48:25.000Z","date":"2021-09-30","kind":"grant","acquired":true,"shares":5204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":5204,"derivative":{"exercise_price":2.18,"exercise_date":"2021-09-30","expiration_date":"2031-09-30","underlying":"Common Stock","underlying_shares":5204},"source":{"system":"sec-edgar","filing":"0001878894-21-000013","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000187889421000013/edgar.xml","form_type":"4"}},{"id":2643728,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T20:18:49.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":3465,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":3465,"derivative":{"exercise_price":3.27,"exercise_date":"2021-06-30","expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":3465},"source":{"system":"sec-edgar","filing":"0001192482-21-000607","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000119248221000607/edgar.xml","form_type":"4"}},{"id":2649490,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-30T23:50:12.000Z","date":"2021-06-29","kind":"grant","acquired":true,"shares":13286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting."}],"balance_after":13286,"derivative":{"exercise_price":28.2,"expiration_date":"2031-06-28","underlying":"Common Stock","underlying_shares":13286},"source":{"system":"sec-edgar","filing":"0001209191-21-044159","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000120919121044159/doc4.xml","form_type":"4"}},{"id":2663046,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T20:28:29.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option will be fully vested and exercisable on June 15, 2022, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.56,"exercise_date":"2022-06-15","expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001192482-21-000517","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000119248221000517/edgar.xml","form_type":"4"}},{"id":2707798,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2021-05-19T01:26:30.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":9000,"derivative":{"exercise_price":18.27,"exercise_date":"2022-05-14","expiration_date":"2031-05-13","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001209191-21-033854","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121033854/doc4.xml","form_type":"4"}},{"id":2707797,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-19T01:26:30.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."},{"field":"shares","element":"transactionShares","label":"F2","text":"The equity award vests over a one year period."}],"balance_after":8250,"source":{"system":"sec-edgar","filing":"0001209191-21-033854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919121033854/doc4.xml","form_type":"4"}},{"id":2760486,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-02T20:14:32.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":4173,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":4173,"derivative":{"exercise_price":3.02,"exercise_date":"2021-03-31","expiration_date":"2031-03-31","underlying":"Common Stock","underlying_shares":4173},"source":{"system":"sec-edgar","filing":"0001247024-21-000011","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000124702421000011/edgar.xml","form_type":"4"}},{"id":2919103,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-05T21:03:18.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":4254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":4254,"derivative":{"exercise_price":2.64,"exercise_date":"2020-12-31","expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":4254},"source":{"system":"sec-edgar","filing":"0001192482-21-000028","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000119248221000028/edgar.xml","form_type":"4"}},{"id":3018177,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-01T20:34:08.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":4325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":4325,"derivative":{"exercise_price":2.275,"exercise_date":"2020-09-30","expiration_date":"2030-09-30","underlying":"Common Stock","underlying_shares":4325},"source":{"system":"sec-edgar","filing":"0001192482-20-000753","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000119248220000753/edgar.xml","form_type":"4"}},{"id":3094887,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-01T21:51:16.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":2130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of this stock option will immediately vest on the date that it is granted."}],"balance_after":2130,"derivative":{"exercise_price":2.6,"exercise_date":"2020-06-30","expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":2130},"source":{"system":"sec-edgar","filing":"0001192482-20-000596","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000119248220000596/edgar.xml","form_type":"4"}},{"id":3104019,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T20:18:41.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option will be fully vested and exercisable on June 18, 2021, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":2.51,"exercise_date":"2021-06-18","expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001192482-20-000550","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000119248220000550/edgar.xml","form_type":"4"}},{"id":3114380,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-06-10T20:21:57.000Z","date":"2020-06-08","kind":"grant","acquired":true,"shares":28100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 8, 2020 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":28100,"derivative":{"exercise_price":8.89,"expiration_date":"2030-06-07","underlying":"Common Stock","underlying_shares":28100},"source":{"system":"sec-edgar","filing":"0001209191-20-035506","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000120919120035506/doc4.xml","form_type":"4"}},{"id":3168895,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-27T21:25:17.000Z","date":"2020-04-24","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in three substantially equal annual installments on April 24, 2021, 2022 and 2023, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":2.58,"expiration_date":"2030-04-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001578563-20-000022","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000157856320000022/primary_doc.xml","form_type":"4"}},{"id":3178955,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-10T01:54:30.000Z","date":"2020-04-08","kind":"grant","acquired":true,"shares":15750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 24 equal monthly installments thereafter."}],"balance_after":15750,"derivative":{"exercise_price":15.63,"expiration_date":"2030-04-07","underlying":"Common Stock","underlying_shares":15750},"source":{"system":"sec-edgar","filing":"0001209191-20-024096","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120024096/doc4.xml","form_type":"4"}},{"id":3178954,"issuer":{"id":1562,"kind":"organization","name":"Travere Therapeutics, Inc.","symbol":"TVTX"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-10T01:54:30.000Z","date":"2020-04-08","kind":"grant","acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5250,"source":{"system":"sec-edgar","filing":"0001209191-20-024096","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1438533/000120919120024096/doc4.xml","form_type":"4"}},{"id":3496860,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-06-07T20:48:25.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":12400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2019 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":12400,"derivative":{"exercise_price":6.33,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":12400},"source":{"system":"sec-edgar","filing":"0001567619-19-013069","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000156761919013069/doc1.xml","form_type":"4"}},{"id":3846602,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-13T16:30:51.000Z","date":"2018-08-09","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in twelve equal monthly installments, beginning one month after the grant date."}],"balance_after":10000,"derivative":{"exercise_price":3.33,"expiration_date":"2028-08-09","underlying":"Common Shares","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-18-051501","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465918051501/a4.xml","form_type":"4"}},{"id":3899560,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-06-08T22:42:23.000Z","date":"2018-06-07","kind":"grant","acquired":true,"shares":18400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":18400,"derivative":{"exercise_price":10.28,"expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":18400},"source":{"system":"sec-edgar","filing":"0001140361-18-027926","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000114036118027926/doc1.xml","form_type":"4"}},{"id":4192930,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-04T16:32:37.000Z","date":"2017-10-02","kind":"grant","acquired":true,"shares":9600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date."}],"balance_after":9600,"derivative":{"exercise_price":7.16,"expiration_date":"2027-10-02","underlying":"Common Shares","underlying_shares":9600},"source":{"system":"sec-edgar","filing":"0001104659-17-060860","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465917060860/a4.xml","form_type":"4"}},{"id":4442016,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-02-16T22:13:09.000Z","date":"2017-02-15","kind":"grant","acquired":true,"shares":82000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in 36 equal monthly installments beginning on March 15, 2017, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":82000,"derivative":{"exercise_price":5.04,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":82000},"source":{"system":"sec-edgar","filing":"0001140361-17-007979","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1517790/000114036117007979/doc1.xml","form_type":"4"}},{"id":4574189,"issuer":{"id":181476,"kind":"organization","name":"Raptor Pharmaceutical Corp","symbol":"RPTP"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2016-10-26T16:45:07.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":30680,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":5.49,"expiration_date":"2022-09-25","underlying":"Common Stock","underlying_shares":30680},"source":{"system":"sec-edgar","filing":"0001140361-16-083655","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1070698/000114036116083655/doc1.xml","form_type":"4"}},{"id":4574188,"issuer":{"id":181476,"kind":"organization","name":"Raptor Pharmaceutical Corp","symbol":"RPTP"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2016-10-26T16:45:07.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":5.13,"expiration_date":"2021-09-22","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001140361-16-083655","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1070698/000114036116083655/doc1.xml","form_type":"4"}},{"id":4574187,"issuer":{"id":181476,"kind":"organization","name":"Raptor Pharmaceutical Corp","symbol":"RPTP"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-26T16:45:07.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":8330,"price":9,"value":74970.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-16-083655","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070698/000114036116083655/doc1.xml","form_type":"4"}},{"id":4574186,"issuer":{"id":181476,"kind":"organization","name":"Raptor Pharmaceutical Corp","symbol":"RPTP"},"owners":[{"id":38196,"kind":"person","name":"Bruhn Suzanne Louise","position":1,"cik":"0001517790","reported_name":"Bruhn Suzanne Louise","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-26T16:45:07.000Z","date":"2016-10-24","kind":"other","acquired":false,"shares":48437,"price":9,"value":435933.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. (\"Raptor\"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland (\"Parent\") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent."}],"balance_after":8330,"source":{"system":"sec-edgar","filing":"0001140361-16-083655","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070698/000114036116083655/doc1.xml","form_type":"4"}}]}